Diabetes, TZDs, and Bone: A Review of the Clinical Evidence
Evidence from rodent and in vitro models suggests that activation of PPAR-γ by thiazolidinediones (TZDs) causes increased bone marrow adiposity and decreased osteoblastogenesis, resulting in bone loss. TZDs are prescribed for the treatment of diabetes, providing an opportunity to determine whether P...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2006-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/PPAR/2006/24502 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Evidence from rodent and in vitro models suggests that activation of PPAR-γ by thiazolidinediones (TZDs) causes increased bone marrow adiposity and
decreased osteoblastogenesis, resulting in bone loss. TZDs are prescribed for
the treatment of diabetes, providing an opportunity to determine whether PPAR-γ activation also impacts bone in humans. In addition, since type 2 diabetes is
associated with higher fracture risk, an understanding of the clinical impact of
TZDs on bone is needed to guide fracture prevention efforts in this population.
This review summarizes current findings regarding type 2 diabetes and increased
fracture risk and then considers the available evidence regarding TZD use and
bone metabolism in humans. |
|---|---|
| ISSN: | 1687-4757 1687-4765 |